Last reviewed · How we verify
desonide 0.1% cream
Desonide is a topical corticosteroid that reduces inflammation by inhibiting the production of pro-inflammatory mediators.
Desonide is a topical corticosteroid that reduces inflammation by inhibiting the production of pro-inflammatory mediators. Used for Eczema, Psoriasis.
At a glance
| Generic name | desonide 0.1% cream |
|---|---|
| Also known as | Locapred |
| Sponsor | Pierre Fabre Medicament |
| Drug class | Corticosteroid |
| Target | Glucocorticoid receptor |
| Modality | Small molecule |
| Therapeutic area | Dermatology |
| Phase | Phase 3 |
Mechanism of action
Desonide works by binding to glucocorticoid receptors in the skin, which leads to a decrease in the production of pro-inflammatory cytokines and other mediators. This results in reduced inflammation and itching. The exact mechanism of action is not fully understood, but it is thought to involve the inhibition of phospholipase A2 and the subsequent reduction in the production of leukotrienes and prostaglandins.
Approved indications
- Eczema
- Psoriasis
Common side effects
- Skin irritation
- Allergic contact dermatitis
- Hypersensitivity reactions
Key clinical trials
- Evaluation of the Vasoconstriction Properties of MC2-01 Cream (PHASE1)
- Efficacy Emollient on Xerosis in Children With Atopic Dermatitis (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- desonide 0.1% cream CI brief — competitive landscape report
- desonide 0.1% cream updates RSS · CI watch RSS
- Pierre Fabre Medicament portfolio CI